Table 2 Summary of JCS guidelines regarding the follow-up of patients with Kawasaki disease, starting at 1 year
From: Cardiovascular imaging in children and adults following Kawasaki disease
Diagnostic testing | Interval | Invasive testing | |
|---|---|---|---|
No or transient CAAa | Exercise ECG + echocardiogram | Once, 5 years after disease b | None |
Small CAA (≤4 mm)a | |||
- Regressed | (Exercise) ECG + echocardiogram | Annual until age 7 Triennial until age 16 | None |
- Persisting | (Exercise) ECG + echocardiogram | 3 months (until normalisation) | None |
- Regressed or persisting | In patients ≥ 10 years after onset, consider MDCT or MRCA at final evaluation. | ||
Medium CAA (>4 − <8 mm)a | |||
A. CAA > 4 − <6 mm | |||
- Regressed | ECG + echocardiogram X-ray + exercise ECG when necessary/feasible MDCT or MRCA | Annual 5 years | Selective CAG on individual basis |
- Persisting | ECG + echocardiogram X-ray + exercise ECG when necessary/feasible MDCT or MRCA | 3–6 months 5 years | Selective CAG on individual basis |
B. CAA 6 − <8 mm | |||
- Regressed | ECG + echocardiogram X-ray + exercise ECG when necessary/feasible MDCT or MRCA Appropriate combination of techniques c | Annual 5 years | Invasive CAG once during convalescence and at time of disappearance of dilatation |
- Persisting | ECG + echocardiogram X-ray + exercise ECG when necessary/feasible MDCT or MRCA Appropriate combination of techniques c | 3–6 months 5 years | Invasive CAG once during convalescence and at time of disappearance of dilatation |
Giant CAA (≥8 mm)a | Tailor-made treatment with appropriate combination of (exercise) ECG, echocardiogram and other techniques c | 3–6 months | Invasive CAG during early convalescence phase |